Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-20

Study Completion Date

2023-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

NCT00970632

Benign Prostatic Hyperplasia (BPH)

COMPLETED PHASE3

Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men

NCT00540124

Benign Prostatic Hyperplasia

COMPLETED PHASE2

A Study in Benign Prostatic Hyperplasia

NCT01152190

Benign Prostatic Hyperplasia

COMPLETED PHASE3

Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

NCT02252367

Prostatic Hyperplasia Lower Urinary Tract Symptoms

COMPLETED PHASE4

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762

Benign Prostatic Hyperplasia Enlarged Prostate

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5mg tadalafil once daily for 14 days

Tadalafil 5mg

Intervention Type DRUG

Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tadalafil 5mg

Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 60-75 yrs
* Recently prescribed 5mg of tadalafil daily for clinical purposes

Exclusion Criteria

* History of diabetes
* history of hypotension including orthostatic hypotension
* History of malignancy or chemo/radiation therapy in the 6 months prior to enrollment
* History of short gut syndrome, gastrointestinal bypass/reduction surgery (Lap band, gastric sleeve, etc.)
* Subjects who cannot refrain from using protein or amino acid supplements for 7 days prior to Visit 2 and 3.
* Alcohol consumption of ≥ 5 units/servings per day
* Concomitant use of

* oral or injectable corticosteroids
* testosterone, insulin like growth factor-1, or similar anabolic agent
* riociguat (Adempas)
* nitroglycerin
* isosorbide dinitrate (Isordil)
* isosorbide mononitrate (Imdur, Monoket)
* doxazosin (Cardura)
* prazosin (Minipress)
* terazosin (Hytrin)
* Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician

Minimum Eligible Age

60 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No